News | 09 May 2025
Agilent inaugurates India Solution Center to accelerate innovation
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The change of name has been carried on pursuant to the Scheme of Amalgamation
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Tatva Chintan Pharma Chem receives export order worth $35, 55,000
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Topiramate is indicated as a treatment of epilepsy and migraine
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This significant milestone enhances our global regulatory standing
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
The Q1 2025 also witnessed a successful launch of Allegra D
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
